Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Antibody Products Will Be An Important Option Until Vaccines Reduce Infections
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
You may also be interested in...
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.